ICLR on Nasdaq

ICON plc

Irish pharmaceutical company

Icon plc (stylized as "ICON") is an Irish-headquartered multinational clinical research organisation (CRO). Icon conducts clinical trials on behalf of pharmaceutical and biotechnology companies and provides services related to drug development and guiding clinical trial progress.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 18, 2026.

Overview

$8.3BRevenue, fiscal 20254
$229.3MNet income, fiscal 20254
1990Founded1

Compare with Incyte, IQVIA Holdings, Inc. or Medpace, or pick any stock.

  • TickerICLR on Nasdaq1
  • Industryconsulting, pharmaceutical industry1
  • HeadquartersIreland1
  • Websiteiconplc.com
  • Legal formpublic limited company1
  • Business addressSouth County Business Park, Leopardstown, Dublin 18, L2 000005
  • Filer categoryLarge accelerated filer5

See how the biggest companies compare on our leaderboards

Icon plc (stylized as "ICON") is an Irish-headquartered multinational clinical research organisation (CRO). Icon conducts clinical trials on behalf of pharmaceutical and biotechnology companies and provides services related to drug development and guiding clinical trial progress.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

5.4%Operating margin4
2.8%Net margin4
0.8%Revenue growth, 20254
2.5%Return on equity4
0.31×Debt to equity4
$862.0MFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Regions

Ireland brought in 39% of the revenue ICON plc broke down this way in fiscal 2025.

  1. Ireland$3.2B439%up 18% from 2024
  2. United States$2.5B431%down 15% from 2024
  3. Rest Of Europe$1.6B419%up 2% from 2024
  4. Rest Of World$951.9M412%up 1% from 2024
Regions by year
Regions202320242025
Ireland$2.3B$2.7B$3.2B
United States$3.3B$3.0B$2.5B
Rest Of Europe$1.6B$1.6B$1.6B
Rest Of World$884.5M$942.6M$951.9M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Selling, general and admin9¢$780.1M
  • Other costs87¢$7.2B
  • Income tax0¢$23.1M
  • Profit3¢$229.3M

Out of $8.3B in revenue.4

Where each dollar of operating cash went, fiscal 2025

  • Capital spending17¢$174.2M
  • Share buybacks72¢$750.0M
  • Kept or used elsewhere11¢$112.0M

Out of $1.0B of cash from operations.4

Financial statements

Revenue78910114$8.3B in 2025+218% since 2018
0$2.5B$5.0B$7.5B$10.0B2018: $2.6B$2.6B20182019: $2.8B$2.8B2019+8%2020: $2.8B$2.8B2020−0%2021: $5.5B$5.5B2021+96%2022: $7.7B$7.7B2022+41%2023: $8.1B$8.1B2023+4%2024: $8.2B$8.2B2024+2%2025: $8.3B$8.3B2025+1%
Operating income78910114$442.8M in 2025+19% since 2018
0$500.0M$1.0B$1.5B2018: $373.4M$373.4M20182019: $433.4M$433.4M2019+16%2020: $391.5M$391.5M2020−10%2021: $378.5M$378.5M2021−3%2022: $795.2M$795.2M2022+110%2023: $904.7M$904.7M2023+14%2024: $1.0B$1.0B2024+14%2025: $442.8M$442.8M2025−57%
Net income78910114$229.3M in 2025−29% since 2018
0$200.0M$400.0M$600.0M$800.0M2018: $322.7M$322.7M20182019: $374.0M$374.0M2019+16%2020: $332.3M$332.3M2020−11%2021: $153.2M$153.2M2021−54%2022: $505.3M$505.3M2022+230%2023: $554.2M$554.2M2023+10%2024: $739.1M$739.1M2024+33%2025: $229.3M$229.3M2025−69%

Every line of the income statement as filed: the last 3 fiscal years, latest first.4

Period ending2025-12-312024-12-312023-12-31
Revenue$8.3B$8.2B$8.1B
Direct costs$6.1B$5.8B$5.7B
Selling, general and administrative$780.1M$728.3M$768.6M
Depreciation and amortization$383.0M$488.5M$586.0M
Transaction and integration related$25.3M$29.6M$44.2M
Restructuring$79.1M$92.1M$45.4M
Goodwill impairment$364.2M$0$0
Impairment of non-financial assets$101.0M$0$0
Total costs and expenses$7.8B$7.2B$7.2B
Income from operations$442.8M$1.0B$904.7M
Interest income$7.1M$8.6M$5.0M
Interest expense-$197.5M-$237.2M-$336.7M
Income before income tax expense$252.5M$803.8M$573.0M
Income tax expense-$23.1M-$64.6M-$18.4M
Income before share of losses from equity method investments$229.3M$739.1M$554.6M
Share of losses from equity method investments$0$0-$383.0K
Net income$229.3M$739.1M$554.2M
Basic (USD per share)$2.92$8.96$6.75
Diluted (USD per share)$2.90$8.90$6.70
Basic (in shares)78.4M shares82.5M shares82.1M shares
Diluted (in shares)79.0M shares83.0M shares82.7M shares

Compare ICON plc with another company

The story

Icon was founded in Ireland, by John Climax and Ronan Lambe in 1990. Since January 2010, Climax has held a position on the board of directors. Lambe retired from the board of directors in 2018.

Between 1991 and 1996, Icon opened offices in the United Kingdom, United States, Germany, and Japan. Two years later, Icon shares began trading on Nasdaq, providing the company with additional capital to support international expansion and acquisitions.

In 2006, Icon acquired Ovation Research Group, expanding its capabilities in health outcomes research and health economics. In 2014, Icon expanded its capabilities in adaptive clinical trial design and execution with the acquisition of Aptiv Solutions.

In 2021, Icon completed its US$12 billion acquisition of PRA Health Sciences. The transaction expanded the company's global clinical research operations and created one of the largest contract research organizations.

On September 4, 2025, Icon announced that Steve Cutler would be stepping down from his position as CEO. Barry Balfe, the company's Chief Operating Officer, was promoted to Chief Executive Officer.

From Wikipedia’s article on Icon plc, shared under CC BY-SA 4.0.6

Leadership

Who has led ICON plc, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Barry Edward Balfe2026–now

Chief financial officer

  1. Nigel Bernard John Clerkin2026–now
1995200020052010201520202025
Board members and other officers (13)

Products and brands

  • clinical trial

Listed on Wikidata.1

Icon provides outsourced drug development, clinical research, and consulting services for pharmaceutical, biotechnology, medical device, and government organizations. The company supports therapies throughout the development lifecycle, from early-stage research and clinical trial design through Phase I–IV clinical trials and commercialization. Its services include clinical trial management, laboratory and imaging services, patient recruitment, data analysis, and regulatory and market access consulting across a range of therapeutic areas.

From Wikipedia’s article on Icon plc, shared under CC BY-SA 4.0.6

Acquisitions

2000: Icon acquired UK-based regulatory consultancy, YRCR Ltd.; Central Laboratory in New York; and bioanalytical consultancy, Pacific Research

2002: Icon acquired clinical research provider, BPA.

2003: Icon acquired Medieval, a UK-based Phase I facility, and US consulting firm, Globomax

2004: Icon acquired medical imaging specialist, Beacon Bioscience Inc.

Read the full text

2006: Icon acquired outcomes research and health economics specialist, Ovation Research Group

2007: Icon acquired European staffing group, DOCS International

2008: Icon acquired US phase I provider, Healthcare Discoveries and US bioanalytical lab, Prevalere Life Sciences

2009: Icon acquired Veeda Laboratories, a UK biomarker lab

2010: Icon acquired Timaq Medical Imaging Inc.

2011: Icon acquired Oxford Outcomes, an international health outcomes consultancy and Firecrest Clinical, a technology provider specialising in site performance and study management

2012: Icon acquired PriceSpective, a global value strategy consultancy and Chinese CRO, BeijingWits

2013: Icon acquired staffing and FSP providers, ClinForce and Assent and Akos, an EU provider of pharmacovigilance and drug safety services

2014: Icon acquired Aptiv Solutions, a market leader in adaptive trial design and execution

2015: Icon acquired MediMedia Pharma Solutions to enhance market access and scientific communications capabilities, and PMG Research Inc., an integrated network of clinical research sites in the US

2016: Icon acquired Clinical Research Management Inc., to extend its presence in the government-sponsored research market

2017: Icon acquired MAPI Group, thereby becoming the world's second-largest provider of late-phase services

2019: Icon acquired Symphony Clinical Research, a leading provider of at-home patient services and site-support services; MediNova, an integrated network of clinical research sites across EMEA; and MolecularMD, to enhance its laboratory offerings in molecular diagnostic testing and immunohistochemistry

2020: Icon acquired MedPass International, a leading European medical device CRO, regulatory and reimbursement consultancy

2021: Icon acquired PRA Health Sciences, a competitor offering clinical research services, for US$12 billion. Upon completion of the transaction, PRA shareholders will own approximately 34 percent of the shares of the combined company and Icon shareholders will own approximately 66 percent.

From Wikipedia’s article on Icon plc, shared under CC BY-SA 4.0.6

Former names

  • ICON PLC /ADR/Feb 14, 2002 to Feb 7, 20135

Timeline

  1. Mar 18, 2026New chief executive Barry Edward Balfe becomes CEO13
  2. Feb 4, 2013Went public Listed on NASDAQ1
  3. 1990Founded Founded1

Filings

275 filings to the SEC since October 2021: 5 annual reports, 31 insider forms, 23 large holders, 216 other. The latest 20:

  1. Oct 8, 20266-K EDGAR
  2. Sep 18, 20264 EDGAR
  3. Sep 18, 20264 EDGAR
  4. Sep 18, 20264 EDGAR
  5. Sep 17, 2026144 EDGAR
  6. Sep 17, 2026144 EDGAR
  7. Sep 16, 2026144 EDGAR
  8. Sep 9, 20266-K EDGAR
  9. Aug 20, 20266-K EDGAR
  10. Aug 18, 20266-K EDGAR
  11. Aug 13, 2026SCHEDULE 13G/A EDGAR
  12. Aug 12, 20264 EDGAR
  13. Aug 12, 20264 EDGAR
  14. Aug 12, 20264 EDGAR
  15. Aug 12, 20264 EDGAR
  16. Aug 12, 20264 EDGAR
  17. Aug 12, 20264 EDGAR
  18. Aug 12, 20264 EDGAR
  19. Aug 12, 20264 EDGAR
  20. Aug 12, 20264 EDGAR

The 275 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 23 such filings since October 2021, the latest 10:

  1. Aug 13, 2026SCHEDULE 13G/A
  2. Aug 6, 2026SCHEDULE 13G/A
  3. May 15, 2026SCHEDULE 13G/A
  4. May 15, 2026SCHEDULE 13G/A
  5. May 15, 2026SCHEDULE 13G
  6. May 6, 2026SCHEDULE 13G
  7. May 6, 2026SCHEDULE 13G
  8. Mar 6, 2026SCHEDULE 13G/A
  9. Feb 17, 2026SCHEDULE 13G/A
  10. Nov 14, 2025SCHEDULE 13G

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Members of Congress who traded it

6 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Aug 14, 2026Kevin HernRepublican, HousePartial sale$15,001 - $50,000−7.9%Report
Mar 5, 2026Kevin HernRepublican, HouseSale$100,001 - $250,000−45.1%Report
Feb 12, 2026Julia LetlowRepublican, HouseSale$1,001 - $15,000−105.4%Report
Sep 4, 2024John JamesRepublican, HouseSale$1,001 - $15,000+84.0%Report
Jun 12, 2024John JamesRepublican, HouseBuy$1,001 - $15,000−87.8%Report
Jan 31, 2023Kevin HernRepublican, HouseSale$1,001 - $15,000+114.0%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25